High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS
Conclusion
These data substantiate that serum and CSF NfL levels reflect disease severity and treatment response in patients with MS and may therefore be a useful biomarker. Baseline serum levels associated with markers of pretreatment disease severity and post-treatment outcomes.
Classification of evidence
This study provides Class II evidence that for patients with aggressive MS, serum NfL levels are associated with disease severity.
Source: Neurology Neuroimmunology and Neuroinflammation - Category: Neurology Authors: Thebault, S., R. Tessier, D., Lee, H., Bowman, M., Bar-Or, A., Arnold, D. L., L. Atkins, H., Tabard-Cossa, V., Freedman, M. S. Tags: Clinical trials Methodology/study design, Clinical trials Observational study (Cohort, Case control), Class II, Multiple sclerosis Article Source Type: research
More News: Brain | Clinical Trials | Disability | Multiple Sclerosis | Neurology | Stem Cell Therapy | Stem Cells | Study | Transplants